Dupilumab
- Generic Name
- Dupilumab
- Brand Names
- Dupixent
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1190264-60-8
- Unique Ingredient Identifier
- 420K487FSG
- Background
Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL), that induce inflammatory and immunological reacti...
- Indication
In the US, dupilumab is indicated for the treatment of patients aged six months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. In Europe and Canada, the drug for this indication is approved for patients aged six years and older. In E...
- Associated Conditions
- Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP), Eosinophilic Esophagitis, Moderate to Severe Asthma, Moderate to Severe Atopic Dermatitis, Oral Steroid-Dependent Asthma (Disorder), Prurigo Nodularis, Severe Asthma, Severe Atopic Dermatitis, Moderate Atopic dermatitis, Moderate Prurigo Nodularis, Severe Prurigo Nodularis
- Associated Therapies
- Add-on therapy, Maintenance therapy
Immunologic Impact of Dupilumab in Patients Suffering From Asthma and Chronic Rhinosinusitis With Polyps
- Conditions
- Interventions
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Dr. Andrew Thamboo, MD
- Target Recruit Count
- 60
- Registration Number
- NCT06556264
Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2024-12-20
- Target Recruit Count
- 30
- Registration Number
- NCT06477653
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Efficacy and Safety of Dupilumab in Combination With Tofacitinib in Moderate to Severe Adult AD Patients
- First Posted Date
- 2024-06-20
- Last Posted Date
- 2024-06-20
- Target Recruit Count
- 220
- Registration Number
- NCT06465732
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 675
- Registration Number
- NCT06461897
- Locations
- 🇺🇸
Medical University of South Carolina /ID# 265113, Charleston, South Carolina, United States
🇬🇧Chelsea and Westminster Hospital /ID# 266389, London, Greater London, United Kingdom
🇺🇸Integrative Skin Science and Research /ID# 265108, Sacramento, California, United States
Study of Dupilumab 300 mg Every Other Week After Endoscopic Sinus Surgery in Patients With Allergic Fungal Rhinosinusitis (AFRS) on a Background Therapy With Intranasal Corticosteroid Spray
- Conditions
- Interventions
Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in Spain
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 150
- Registration Number
- NCT06415175
- Locations
- 🇪🇸
Investigational Site Number : 7240008, Seville, Sevilla, Spain
🇪🇸Investigational Site Number : 7240003, Barcelona, Spain
🇪🇸Investigational Site Number : 7240012, Palma de Mallorca, Spain
Study in Adults With Severe Chronic Rhinosinusitis With Nasal Polyposis Treated With Dupilumab in France
- Conditions
- Interventions
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 150
- Registration Number
- NCT06393946
- Locations
- 🇫🇷
Investigational Site Number: 250.0001, Nantes, France
Short-Term Linvoseltamab Treatment, on Top of Chronic Dupilumab Treatment, for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 6
- Registration Number
- NCT06369467
- Locations
- 🇺🇸
Emory University- Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
Dupilumab for Eosinophilic Esophagitis With Severe Strictures
- First Posted Date
- 2024-04-08
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 30
- Registration Number
- NCT06352073
- Locations
- 🇺🇸
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
- First Posted Date
- 2024-03-05
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 18
- Registration Number
- NCT06293053
- Locations
- 🇺🇸
Mission Dermatology Center- Site Number : 8400011, Rancho Santa Margarita, California, United States
🇺🇸Pediatric Center Of Excellence- Site Number : 8400005, Coral Gables, Florida, United States
🇺🇸USF Health - Dermatology and Cutaneous Surgery - Davis Blvd Location (Pediatric Dermatology)- Site Number : 8400003, Tampa, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.